Valuation: ImpediMed Limited

Market Cap 18.31M 12.23M 11.14M 10.31M 9.33M 17.5M 1.14B 125M 49.44M 617M 45.87M 44.91M 1.95B P/E 2027 *
-1.25x
P/E 2028 * -2.5x
Enterprise Value 27.61M 18.43M 16.8M 15.55M 14.06M 26.38M 1.72B 188M 74.55M 930M 69.16M 67.71M 2.95B EV / Sales 2027 *
1.61x
EV / Sales 2028 * 1.43x
Free-Float
84.72%
Yield 2027 *
-
Yield 2028 * -
1 week+25.00%
Current month+25.00%
1 month+25.00%
6 months-16.67%
Current year-85.29%
1 week 0
Extreme 0.004
0
1 month 0
Extreme 0.003
0
Current year 0
Extreme 0.003
0.04
1 year 0
Extreme 0.003
0.04
3 years 0
Extreme 0.003
0.16
5 years 0
Extreme 0.003
0.24
10 years 0
Extreme 0.003
1.35
Manager TitleAgeSince
Chief Executive Officer - 07/05/2026
Director of Finance/CFO - 20/11/2023
Chief Tech/Sci/R&D Officer - 26/09/2023
Director TitleAgeSince
Chairman - -
Chairman - 26/02/2024
Director/Board Member - 28/09/2023
Date Insider Type Main position Quantity % Market Cap. Importance
16/01/26 Buy

Chairman

146,408 0.0072%
16/01/26 Buy

Director

100,563 0.0049%
16/01/26 Buy

Director

100,563 0.0049%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+25.00%-86.49%-96.15% 12.23M
-0.58%-1.53%+20.04%+47.67% 255B
-0.45%-1.98%+2.32%+9.52% 160B
-3.26%-7.42%-27.88%+33.40% 141B
-1.49%-2.74%-55.68%-20.89% 62.31B
-1.28%-1.81%+20.76%+55.28% 59.73B
-0.05%+0.05%+5.92%-12.43% 53.49B
-1.12%+1.35%+21.43%+54.96% 49.43B
-2.06%-1.24%+21.32%+74.31% 44.87B
-5.15%-13.06%-3.69%+48.93% 42.57B
Average -1.66%-0.47%-8.20%+19.46% 87B
Weighted average by Cap. -1.47%-3.60%+1.72%+32.08%

Financials

2027 *2028 *
Net sales 17.1M 11.42M 10.4M 9.63M 8.71M 16.34M 1.07B 116M 46.17M 576M 42.83M 41.93M 1.83B 22.5M 15.02M 13.69M 12.67M 11.46M 21.5M 1.4B 153M 60.75M 758M 56.35M 55.17M 2.4B
Net income -16.1M -10.75M -9.79M -9.07M -8.2M -15.38M -1B -110M -43.47M -542M -40.32M -39.48M -1.72B -9.6M -6.41M -5.84M -5.41M -4.89M -9.17M -599M -65.34M -25.92M -323M -24.04M -23.54M -1.02B
Net Debt 9.3M 6.21M 5.66M 5.24M 4.74M 8.89M 580M 63.29M 25.11M 313M 23.29M 22.8M 993M 13.89M 9.27M 8.45M 7.82M 7.07M 13.27M 866M 94.51M 37.49M 468M 34.78M 34.05M 1.48B
Projected Income Statement - Annual - ImpediMed Limited
Logo ImpediMed Limited
ImpediMed Limited is an Australia-based medical technology company. The Company uses bioimpedance spectroscopy (BIS) technology to generate data to maximize patient health. The Company designs and manufactures medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the noninvasive clinical assessment and monitoring of fluid status and tissue composition. The Company’s SOZO Digital Health Platform is a Food and Drug Administration (FDA)-cleared bioimpedance spectroscopy (BIS) solution for the clinical assessment of lymphedema. Its SOZO Applications include L-Dex Analysis for Lymphedema, BodyComp Analysis, Segmental BodyComp Analysis, and HF-Dex Analysis for Heart Failure. Its product SFB7 measures fluid status and tissue composition for clinical and research applications. Its ImpediVET is a single-channel, tetrapolar bioimpedance spectroscopy (BIS) device that measures fluid status and tissue composition for veterinary applications.
Employees
66
Date Price Change Volume
20/11/26 A$0.005000 0.00% 3,415,758
19/11/26 A$0.005000 0.00% 3,367,291
18/11/26 A$0.005000 +25.00% 5,903,791
17/11/26 A$0.004000 0.00% 164,066
16/11/26 A$0.004000 0.00% 20,408
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - ImpediMed Limited
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
0.005000AUD
Average target price
0.0195AUD
Spread / Average Target
+290.80%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - ImpediMed Limited